NextCure Raises $21.5 Million in PIPE Financing
NextCure Inc. has closed a $21.5 million private placement, selling 708,428 shares of common stock at $8.52 each and pre-funded warrants for 1,815,049 shares at $8.519 per warrant. The financing, led by Ikarian Capital and others, extends NextCure's cash runway into early 2027 to support its antibody drug conjugate programs. H.C. Wainwright & Co. acted as the exclusive placement agent.
NextCure Inc. has announced the closing of a $21.5 million private placement, in which the company sold 708,428 shares of common stock at $8.52 per share and pre-funded warrants to purchase up to 1,815,049 shares of common stock at $8.519 per warrant. The securities were sold in a private placement exempt from SEC registration requirements, with H.C. Wainwright & Co. acting as the exclusive placement agent. The financing was led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, and Exome Asset Management, and will extend NextCure’s cash runway into the first half of 2027, supporting ongoing development of its antibody drug conjugate programs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576606-en) on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
